Hugo Ribeiro Zanetti1,2, Leonardo Roever3, Alexandre Gonçalves4,3,5,6, Elmiro Santos Resende3. 1. Master Institute of Education President Antônio Carlos, Avenida Minas Gerais, 1889 - Centro, Araguari, MG, 38.440-046, Brazil. hugo.zanetti@hotmail.com. 2. Department of Clinical Research, Federal University of Uberlândia, Uberlândia, MG, Brazil. hugo.zanetti@hotmail.com. 3. Department of Clinical Research, Federal University of Uberlândia, Uberlândia, MG, Brazil. 4. Master Institute of Education President Antônio Carlos, Avenida Minas Gerais, 1889 - Centro, Araguari, MG, 38.440-046, Brazil. 5. Paulista University, Brasília, DF, Brazil. 6. Atenas College, Paracatu, MG, Brazil.
Abstract
PURPOSE OF REVIEW: This clinical update is intended to focus in relationship between HIV infection and use of antiretroviral therapy (ART) and statin. RECENT FINDINGS: Though ART significantly changed the course of HIV infection, it is related to numerous side effects principally to the lipid profile. In this way, statins became one of the most used lipid-lowering therapies in this population. In our clinical update, we evaluated studies that demonstrate the relationship and molecular mechanisms that HIV infection and ART use trigger dyslipidemia and also the use of statin to reduce this condition. We have demonstrated that use of statin can be used in dyslipidemic HIV-infected people as long as there is no drug interaction with ART. Recently, studies using rosuvastatin have shown greater effects when compared to the other statins.
PURPOSE OF REVIEW: This clinical update is intended to focus in relationship between HIV infection and use of antiretroviral therapy (ART) and statin. RECENT FINDINGS: Though ART significantly changed the course of HIV infection, it is related to numerous side effects principally to the lipid profile. In this way, statins became one of the most used lipid-lowering therapies in this population. In our clinical update, we evaluated studies that demonstrate the relationship and molecular mechanisms that HIV infection and ART use trigger dyslipidemia and also the use of statin to reduce this condition. We have demonstrated that use of statin can be used in dyslipidemic HIV-infected people as long as there is no drug interaction with ART. Recently, studies using rosuvastatin have shown greater effects when compared to the other statins.
Authors: Patrick W G Mallon; John Miller; Jason C Kovacic; Julia Kent-Hughes; Richard Norris; Katherine Samaras; Michael P Feneley; David A Cooper; Andrew Carr Journal: AIDS Date: 2006-04-24 Impact factor: 4.177
Authors: Cecilia M Shikuma; Louie Mar A Gangcuangco; Deirdre A Killebrew; Daniel E Libutti; Dominic C Chow; Beau K Nakamoto; Chin Yuan Liang; Cris I P Milne; Lishomwa C Ndhlovu; Jason D Barbour; Bruce T Shiramizu; Mariana Gerschenson Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Monica Malta; Cosme M F P da Silva; Monica Mf Magnanini; Andrea L Wirtz; André R S Perissé; Chris Beyrer; Steffanie A Strathdee; Francisco I Bastos Journal: BMC Public Health Date: 2015-03-07 Impact factor: 3.295
Authors: Stefan Esser; Lewin Eisele; Birte Schwarz; Christina Schulze; Volker Holzendorf; Nobert H Brockmeyer; Martin Hower; Friedhelm Kwirant; Roland Rudolph; Till Neumann; Nico Reinsch Journal: J Int AIDS Soc Date: 2014-11-02 Impact factor: 5.396